ABT Abbott Laboratories
- Official Name: ABBOTT LABORATORIES
- Headquarters: 100 Abbott Park Road, Abbot Park, ABBOTT PARK, IL, 60064-3500 US
- CEO: Robert B. Ford
- Website: abbott.com
- Key Investor: VANGUARD GROUP INC | 9.76%
- Dedicated Investor: LIVELSBERGER FINANCIAL ADVISORY | 18.05%
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-18 | 1 | Won by 4.187 | (0.439) - (4.626) | ||
| 2025-07-25 | 2 | Won by 0.183 | 5.124 - 4.941 | ||
| 2025-07-29 | 2R | Won by 1.756 | 1.374 - (0.382) | ||
| 2025-08-01 | 3 | Won by 1.605 | 1.056 - (0.549) | ||
| 2025-08-07 | 1R | Won by 0.808 | 0.706 - (0.102) | ||
| 2025-08-08 | 4 | Won by 0.106 TOTW | 5.190 - 5.084 | ||
| 2025-08-12 | 3R | Lost by 3.119 | (0.449) - 2.670 | ||
| 2025-08-15 | 5 | Won by 0.716 | (0.486) - (1.202) | ||
| 2025-08-20 | 1R | Lost by 0.942 | 0.688 - 1.630 | ||
| 2025-08-21 | 2R | Won by 0.277 | (0.992) - (1.269) | ||
| 2025-08-22 | 6 | Won by 4.274 | 3.923 - (0.351) | ||
| 2025-08-29 | 7 | Lost by 1.060 | 0.051 - 1.111 | ||
| 2025-09-04 | 3R | Won by 4.179 | 0.480 - (3.699) | ||
| 2025-09-05 | 8 | Won by 1.554 | 0.255 - (1.299) | ||
| 2025-09-11 | 4R | Won by 0.595 | 2.494 - 1.899 | ||
| 2025-09-12 | 9 | Lost by 0.672 | 0.597 - 1.269 | ||
| 2025-09-18 | 5R | Lost by 1.566 | 0.329 - 1.895 | ||
| 2025-09-19 | 10 | Lost by 0.067 | 1.743 - 1.810 | ||
| 2025-09-26 | 11 | Lost by 3.738 | (1.807) - 1.931 | ||
| 2025-10-03 | 12 | Lost by 1.946 | 0.718 - 2.664 | ||
| 2025-10-10 | 13 | Lost by 3.879 | (1.471) - 2.408 | ||
| 2025-10-17 | 14 | Lost by 3.493 | (2.675) - 0.818 | ||
| 2025-10-24 | 15 | Lost by 1.242 | (1.279) - (0.037) |
Latest News

Abbott Laboratories (ABT) Launches Ensure Max Protein As Undervalued View Faces A Fresh Test
Abbott Laboratories (ABT) just introduced Ensure Max Protein 3-in-1 Muscle Support, a powder that combines protein, creatine and HMB in a single produ...

Countdown to Abbott (ABT) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Beyond analysts' top-and-bottom-line estimates for Abbott (ABT), evaluate projections for some of its key metrics to gain a better insight into h...

Why SCHD’s Income Is Unshakable This Year: 6 Dividend Aristocrats Doing the Heavy Lifting
Six Dividend Aristocrats shoulder a big chunk of SCHD's 3.8% yield, but two of them are paying dividends that their earnings barely cover. Here i...

Haemonetics Gains 149.3% in a Year: What's Driving the Rally?
HAE shares surged 149.3% in a year, fueled by strong Plasma and MedSurg growth, rising product demand and an upbeat fiscal 2027 revenue outlook.

Reasons to Add STE Stock to Your Portfolio Right Now
STERIS' strong Healthcare growth, improving AST prospects and rising Life Sciences demand bolster its outlook, despite tariff and inflationary pr...

Is it Apt to Retain Medtronic Stock in Your Portfolio Now?
MDT expands in cardiac ablation, robotics, hypertension and digital surgery, but tariff, inflation and currency risks are likely to pressure margins.
TD Cowen Reiterates Buy on Abbott Laboratories, Maintains $135 Price Target
TD Cowen analyst Joshua Jennings reiterates Abbott Laboratories (NYSE:ABT) with a Buy and maintains $135 price target.

Is Medtronic Stock A Buy Now That Sales Growth Has Picked Up?
Investors considering Medtronic (MDT) stock face an immediate concern: the shares returned 1.9% over the past year, trailing the 17.3% gain for the S&...

Is Boston Scientific Stock Riskier Than It Was A Year Ago?
Investors in Boston Scientific (BSX) hold stakes in a medical device maker that grew revenue 13.5% over the twelve months to June 2026. Yet the shares...

3 Overlooked Healthcare Dividend Stocks That Could Keep Paying for Decades
Most income investors chase flashy yields and overlook the quiet compounders that have raised their dividends through recessions, rate shocks, and glo...

Is it Apt to Retain Prestige Consumer Stock in Your Portfolio Now?
PBH's brand-building, acquisitions and e-commerce growth support fiscal 2027 revenue gains, but competition and currency risks remain key challen...

Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
HAE's MedSurg growth and NexSys PCS adoption support its prospects, but competitive pressures and unfavorable currency movements pose risks.

What Could BSX Stock Be Worth In Three Years?
Boston Scientific (BSX) stock currently trades at 17.2 times earnings. This compares to an average multiple of 55.9 over the last twelve quarter-ends,...

Longleaf Partners Global Fund Q3 2026 Portfolio Review
Biopharma company Regeneron reported a solid set of results, with key drug Dupixent continuing to outpace our and the market's growth expectation...

Medtronic Pays More Today. Abbott Raises Its Dividend Faster. Which Stock Wins?
Both are Dividend Kings with decades of consecutive raises, but Medtronic and Abbott reward income investors in fundamentally different ways, and choo...

Bet on These Healthcare ETFs to Benefit From the Aging US Population
With the US population aging rapidly, three healthcare ETFs offer exposure to companies developing treatments, drugs and medical devices for age-relat...

Longleaf Partners Fund Q3 2026 Portfolio Review
The market is regaining confidence in Avantorâs ability to grow organically and in Emmanuel Lignerâs turnaround plan.

Abbott Laboratories (ABT) Is A Key Player In Closed Loop Neurostimulation
Abbott Laboratories (NYSE:ABT) has been identified as a leading group advancing closed-loop neurostimulation in bioelectronic medicine devices. The co...

The Market Is Flashing Warning Signals Not Seen in Years. Here’s Why I Just Bought 3 of SCHD’s Dividend Kings.
The market's warning signs are driving me to shift my portfolio towards high-quality holdings.

mHealth Solutions Market Forecasts Growth from $109.05B (2026) to $275.44B by 2031, Profiling Philips, Medtronic, Abbott, Dexcom, ResMed & 20 Other Key Players
388-Page Report Delivers 2025 Market Share Rankings, Vendor Valuation Metrics and End-User Buying Criteria as Asia Pacific Emerges as the Fastest-Grow...

Is This the Right Time to Retain Omnicell Stock in Your Portfolio?
OMCL raises its 2026 earnings outlook on cost discipline and efficiency, but rising memory costs and delayed Titan XT adoption pose challenges.

Freenome Sinks 11% Despite “Clinically Meaningful” Gains for Next-Gen Colon Cancer Blood Test
Key TakeawaysFreenome shares fell 11% today after an updated version of its SimpleScreen CRC blood test raised precancer detection to 18. 2%, up from ...

Should You Add Abbott Stock to Your Portfolio Ahead of Q3 Earnings?
ABT's Q3 earnings are likely to have benefited from Diagnostics growth, Medical Device momentum and Nutrition innovations, while its valuation be...

Global Bioelectronic Medicine Device Market 2026 | Capitalize on 17% CAGR Through 2030 as Medtronic, Abbott, Boston Scientific and LivaNova Advance Closed-Loop Neurostimulation
Dublin, Oct. 13, 2026 (GLOBE NEWSWIRE) -- "Bioelectronic Medicine Device Market Global Report 2026" has been added to ResearchAndMarkets.com...

Abbott (ABT) Gains As Market Dips: What You Should Know
Abbott (ABT) closed the most recent trading day at $101.82, moving +2.23% from the previous trading session.

Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026?
Abbott trades at a 18x forward P/E with $7.4B in free cash flow, while Intuitive Surgical commands a 39x multiple backed by zero debt and 20% revenue ...

Ascensia leads $36M funding round for glucose sensor startup
Ascensia also struck an exclusive sales agreement with Sava, which is making a wearable to continuously monitor glucose and other biomarkers.

Has Medtronic Stock Become A Different Bet?
Medtronic (MDT) stock trades at 21.6 times earnings, sitting about level with the S&P 500 at 21.9. Shareholders paying that market price need to k...
Abbott Laboratories (NYSE:ABT): A Quality Stock With Durable Fundamentals
Abbott passes key quality investing filters with strong ROIC, cash-backed earnings, and steady growth, though valuation and liquidity risks remain.